July 6, 2016 07:44 AM EDTUpdated July 10, 02:16 PM
R&D

Biotech IPOs may still be a bright spot, but the light has dimmed

John Carroll

Editor & Founder

Gen­Sight has been play­ing in one of the hottest sec­tors in biotech, de­vel­op­ing new gene ther­a­pies for rare eye dis­eases. But the French biotech nev­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

No­var­tis used a PRV to speed Kisqal­i's lat­est in­di­ca­tion, FDA says

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times